News and updates

Current press releases, talks and reports

NEO New Oncology AG’s Blood Test NEOliquid Finds Targeted Therapy for Cancer Patient

Researchers from Kantonsspital Luzern and NEO New Oncology AG publish case study on patient benefiting from comprehensive blood-based diagnostics

Cologne, November 25, 2015 – Researchers from Kantonsspital Luzern and NEO New Oncology AG jointly published a report in the December issue of the Journal of Thoracic Oncology describing the clinical efficacy of NEO New Oncology AG’s novel liquid biopsy assay NEOliquid.

NEOliquid is a non-invasive blood test that identifies clinically relevant, cancer-specific point mutations, insertions, deletions and gene fusions in circulating cell-free DNA down to an allele frequency of 0.1%. In addition, NEOliquid is able to detect copy number alterations in tiny amounts of circulating tumor DNA.

In the case study, conventional tissue diagnostics had not been able to detect the relevant mutation in a patient with metastatic lung adenocarcinoma, who had been extensively pretreated with EGFR-inhibitors, chemotherapy, neurosurgery, and brain radiation.

NEOliquid identified EGFR T790M conferring resistance to the previously applied drugs in a simple blood sample. As a result, the patient was treated with the third-generation EGFR-inhibitor AZD9291. The disease rapidly responded to the treatment, with both the primary tumor and metastases shrinking, and the patient's condition improving. Follow up controls with NEOliquid every 2 weeks showed a gradual decrease of the resistance mutation in the patient’s blood over time, confirming the efficacy of the drug. As of today, the clinicians observed no clinical, radiological or genomic signs of progression, and the patient remains well and on treatment.

“Blood-based genomic diagnostics has the potential to revolutionize cancer care,” said PD Dr. Lukas C. Heukamp, Chief Medical Director of NEO New Oncology AG. “We are very excited that with NEOliquid we are able to offer the clinician a tool to understand the patient’s cancer as a whole. NEOliquid facilitates detection of all therapeutically relevant genomic alterations without the need for a painful and often risky re-biopsy, while also being a powerful tool to display genomic differences between primary tumors and corresponding metastases, thereby capturing the entire heterogeneity of the disease.”

About NEO New Oncology AG
NEO New Oncology AG’s “NEO” diagnostic platform allows doctors to determine the optimal targeted therapy for their patients. This also includes the possibility to participate in appropriate clinical trials. NEO identifies all therapy-relevant genetic alterations from standard clinical material quickly, reliably and irrespective of indications. With NEO, point mutations, as well as amplifications, small insertions or deletions and selected known and new translocations can be detected from a single patient sample. NEO New Oncology AG works together with renowned cancer experts to make the latest scientific findings available for improvements in patient care.

Dr. Jutta Fritz
NEO New Oncology AG

Press Release
#09 2015

to download